Search Results - "GUBA, Susan C"

PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer by PATEL, Jyoti D, SOCINSKI, Mark A, GUBA, Susan C, JINGYI LIU, FRIMODT-MOLLER, Bente, JOHN, William J, OBASAJU, Coleman K, PENNELLA, Eduardo J, BONOMI, Philip, GOVINDAN, Ramaswamy, GARON, Edward B, REYNOLDS, Craig H, SPIGEL, David R, OLSEN, Mark R, HERMANN, Robert C, JOTTE, Robert M, BECK, Thaddeus, RICHARDS, Donald A

“…PointBreak (A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer) compared the efficacy and safety of…”
Get full text

Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer by Melisi, Davide, Oh, Do-Youn, Hollebecque, Antoine, Calvo, Emiliano, Varghese, Anna, Borazanci, Erkut, Macarulla, Teresa, Merz, Valeria, Zecchetto, Camilla, Zhao, Yumin, Gueorguieva, Ivelina, Man, Michael, Gandhi, Leena, Estrem, Shawn T, Benhadji, Karim A, Lanasa, Mark C, Avsar, Emin, Guba, Susan C, Garcia-Carbonero, Rocio

“…BackgroundWe assessed the safety, efficacy, and pharmacokinetics of the transforming growth factor beta (TGFβ) receptor inhibitor galunisertib co-administered…”
Get full text

Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway by Herbertz, Stephan, Sawyer, J Scott, Stauber, Anja J, Gueorguieva, Ivelina, Driscoll, Kyla E, Estrem, Shawn T, Cleverly, Ann L, Desaiah, Durisala, Guba, Susan C, Benhadji, Karim A, Slapak, Christopher A, Lahn, Michael M

“…Transforming growth factor-beta (TGF-β) signaling regulates a wide range of biological processes. TGF-β plays an important role in tumorigenesis and…”
Get full text

A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer by Nadal, Ernest, Saleh, Mansoor, Aix, Santiago Ponce, Ochoa-de-Olza, Maria, Patel, Sandip Pravin, Antonia, Scott, Zhao, Yumin, Gueorguieva, Ivelina, Man, Michael, Estrem, Shawn T, Liu, Jiangang, Avsar, Emin, Lin, Wen Hong, Benhadji, Karim A, Gandhi, Leena, Guba, Susan C, Diaz, Inmaculada Ales

“…In this phase Ib/II open-label study, tumor immune suppression was targeted in patients with advanced refractory solid tumors and patients with…”
Get full text

PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer by Zinner, Ralph G, Obasaju, Coleman K, Spigel, David R, Weaver, Robert W, Beck, J Thaddeus, Waterhouse, David M, Modiano, Manuel R, Hrinczenko, Borys, Nikolinakos, Petros G, Liu, Jingyi, Koustenis, Andrew G, Winfree, Katherine B, Melemed, Symantha A, Guba, Susan C, Ortuzar, Waldo I, Desaiah, Durisala, Treat, Joseph A, Govindan, Ramaswamy, Ross, Helen J

“…PRONOUNCE compared the efficacy and safety of pemetrexed+carboplatin followed by pemetrexed (Pem+Cb) with paclitaxel+carboplatin+bevacizumab followed by…”
Get more information

Phase III Study of Pemetrexed Plus Carboplatin Compared With Etoposide Plus Carboplatin in Chemotherapy-Naive Patients With Extensive-Stage Small-Cell Lung Cancer by SOCINSKI, Mark A, SMIT, Egbert F, JASSEM, Jacek, DEDIU, Mircea, SHENGYAN HONG, VISSEREN-GRUL, Carla, HANAUSKE, Axel-Rainer, OBASAJU, Coleman K, GUBA, Susan C, THATCHER, Nick, LORIGAN, Paul, KONDURI, Kartik, RECK, Martin, SZCZESNA, Aleksandra, BLAKELY, Johnetta, SERWATOWSKI, Piotr, KARASEVA, Nina A, CIULEANU, Tudor

“…Following a phase II trial in which pemetrexed-platinum demonstrated similar activity to that of historical etoposide-platinum controls, a phase III study was…”
Get full text

A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma by Brandes, Alba A, Carpentier, Antoine F, Kesari, Santosh, Sepulveda-Sanchez, Juan M, Wheeler, Helen R, Chinot, Olivier, Cher, Lawrence, Steinbach, Joachim P, Capper, David, Specenier, Pol, Rodon, Jordi, Cleverly, Ann, Smith, Claire, Gueorguieva, Ivelina, Miles, Colin, Guba, Susan C, Desaiah, Durisala, Lahn, Michael M, Wick, Wolfgang

“…The combination of galunisertib, a transforming growth factor (TGF)-β receptor (R)1 kinase inhibitor, and lomustine was found to have antitumor activity in…”
Get full text

Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma by Wick, Antje, Desjardins, Annick, Suarez, Cristina, Forsyth, Peter, Gueorguieva, Ivelina, Burkholder, Tiana, Cleverly, Ann Louise, Estrem, Shawn T., Wang, Shuaicheng, Lahn, Michael M., Guba, Susan C., Capper, David, Rodon, Jordi

“…Summary Purpose Galunisertib, a TGF-β inhibitor, has demonstrated antitumor effects in preclinical and radiographic responses in some patients with malignant…”
Get full text

Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes by Santini, Valeria, Valcárcel, David, Platzbecker, Uwe, Komrokji, Rami S, Cleverly, Ann L, Lahn, Michael M, Janssen, Jan, Zhao, Yumin, Chiang, Alan, Giagounidis, Aristoteles, Guba, Susan C, Gueorguieva, Ivelina, Girvan, Allicia C, da Silva Ferreira, Mariana, Bhagat, Tushar D, Pradhan, Kith, Steidl, Ulrich, Sridharan, Ashwin, Will, Britta, Verma, Amit

“…Overactivation of TGF-β signaling is observed in myelodysplastic syndromes (MDS) and is associated with dysplastic hematopoietic differentiation. Galunisertib,…”
Get full text

Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer by Sweeney, Christopher J, Percent, Ivor J, Babu, Sunil, Cultrera, Jennifer L, Mehlhaff, Bryan A, Goodman, Oscar B, Morris, David S, Schnadig, Ian D, Albany, Costantine, Shore, Neal D, Sieber, Paul R, Guba, Susan C, Zhang, Wei, Wacheck, Volker, Donoho, Gregory P, Szpurka, Anna M, Callies, Sophie, Lin, Boris Kin, Bendell, Johanna C

“…To report efficacy and safety of samotolisib (LY3023414; PI3K/mTOR dual kinase and DNA-dependent protein kinase inhibitor) plus enzalutamide in patients with…”
Get full text

Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine by Capper, David, von Deimling, Andreas, Brandes, Alba A, Carpentier, Antoine F, Kesari, Santosh, Sepulveda-Sanchez, Juan M, Wheeler, Helen R, Chinot, Olivier, Cher, Lawrence, Steinbach, Joachim P, Specenier, Pol, Rodon, Jordi, Cleverly, Ann, Smith, Claire, Gueorguieva, Ivelina, Miles, Colin, Guba, Susan C, Desaiah, Durisala, Estrem, Shawn T, Lahn, Michael M, Wick, Wolfgang

“…Galunisertib, a Transforming growth factor-βRI (TGF-βRI) kinase inhibitor, blocks TGF-β-mediated tumor growth in glioblastoma. In a three-arm study of…”
Get full text

Quality of life analyses from the randomized, open-label, phase III PointBreak study of pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexed-bevacizumab versus paclitaxel-carboplatin-bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer by Spigel, David R, Patel, Jyoti D, Reynolds, Craig H, Garon, Edward B, Hermann, Robert C, Govindan, Ramaswamy, Olsen, Mark R, Winfree, Katherine B, Chen, Jian, Liu, Jingyi, Guba, Susan C, Socinski, Mark A, Bonomi, Philip

“…Treatment impact on quality of life (QoL) informs treatment management decisions in advanced nonsquamous non-small-cell lung cancer (NS NSCLC). QoL outcomes…”
Get more information

Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin by Reck, Martin, Thatcher, Nick, Smit, Egbert F, Lorigan, Paul, Szutowicz-Zielinska, Ewa, Liepa, Astra M, Winfree, Katherine B, Peterson, Patrick, Guba, Susan C, Socinski, Mark A

“…Abstract Background Small cell lung cancer (SCLC) is associated with poor prognosis due to its early metastatic potential and lack of improved outcomes with…”
Get full text

Pemetrexed Therapy in Elderly Patients With Good Performance Status: Analysis of Two Phase III Trials of Patients With Nonsquamous Non–Small-Cell Lung Cancer by Gridelli, Cesare, Brodowicz, Thomas, Langer, Corey J, Peterson, Patrick, Islam, Mominul, Guba, Susan C, Moore, Patti, Visseren-Grul, Carla M, Scagliotti, Giorgio

“…Micro-Abstract The efficacy and safety of pemetrexed treatment was evaluated in elderly patients with nonsquamous advanced non–small-cell lung cancer and a…”
Get full text

Treatment Rationale and Study Design for the PointBreak Study: A Randomized, Open-label Phase III Study of Pemetrexed/Carboplatin/Bevacizumab Followed by Maintenance Pemetrexed/Bevacizumab Versus Paclitaxel/Carboplatin/Bevacizumab Followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer by Patel, Jyoti D, Bonomi, Philip, Socinski, Mark A, Govindan, Ramaswamy, Hong, Shengyan, Obasaju, Coleman, Pennella, Eduardo J, Girvan, Allicia C, Guba, Susan C

“…Abstract We present the treatment rationale and study design of the PointBreak study, a phase III study of pemetrexed/carboplatin/bevacizumab induction…”
Get full text

Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed-Carboplatin-Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB/IV Nonsquamous Non–Small-Cell Lung Cancer by Reynolds, Craig H, Patel, Jyoti D, Garon, Edward B, Olsen, Mark R, Bonomi, Philip, Govindan, Ramaswamy, Pennella, Eduardo J, Liu, Jingyi, Guba, Susan C, Li, Shi, Spigel, David R, Hermann, Robert C, Socinski, Mark A, Obasaju, Coleman K

“…Micro-Abstract The present exploratory analysis of the PointBreak trial showed no significant differences between African Americans and whites for overall…”
Get full text

Hyperhomocysteinemia and the Endocrine System: Implications for Atherosclerosis and Thrombosis by Fonseca, Vivian, Guba, Susan C, Fink, Louis M

“…I. Introduction II. Methionine-Homocysteine Metabolism A. Methionine metabolism B. Regulation of remethylation and transsulfuration of H(e) III. Nomenclature…”
Get full text

Phase 1b dose-escalation and cohort-expansion study of the safety, tolerability, and efficacy of a novel transforming growth factor-β receptor I kinase inhibitor (galunisertib [G]) administered in combination with the anti-PD-L1 antibody (durvalumab [D]) in recurrent or refractory metastatic pancreatic cancer by Melisi, Davide, Guba, Susan C., Karasarides, Maria, Andre, Valerie

“…Abstract only TPS501 Background: Transforming growth factor-β (TGF-β) can suppress adaptive and innate anti-tumor immune responses. G (LY2157299) is an oral…”
Get full text

A phase Ib dose-escalation and cohort-expansion study of safety and activity of the transforming growth factor (TGF) β receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer by Melisi, Davide, Hollebecque, Antoine, Oh, Do-Youn, Calvo, Emiliano, Varghese, Anna M., Borazanci, Erkut Hasan, Mercade, Teresa Macarulla, Simionato, Francesca, Park, Joon Oh, Bendell, Johanna C., Faivre, Sandrine J., Zhao, Yumin, Gueorguieva, Ivelina, Man, Michael, Estrem, Shawn, Benhadji, Karim Adnane, Lanasa, Mark, Guba, Susan C., Garcia-Carbonero, Rocio

“…Abstract only 4124 Background: Pancreatic cancer (PC) is characterized by a highly immunosuppressive microenvironment, and immune checkpoint inhibitors as…”
Get full text

A phase II study of galunisertib monotherapy or galunisertib plus lomustine compared to lomustine monotherapy in recurrent glioblastoma by Brandes, Alba Ariela, Carpentier, Antoine F, Kesari, Santosh, Sepulveda, Juan, Wheeler, Helen, Chinot, Olivier L., Cher, Lawrence, Steinbach, Joachim Peter, Specenier, Pol, Cleverly, Ann, Smith, Claire, Gueorguieva, Ivelina, Guba, Susan C., Desaiah, Durisala, Lahn, Michael M. F., Wick, Wolfgang

“…Abstract only…”
Get full text